Affimed Announces Acceptance Of An Abstract On Preclinical Data Of Its Innate Cell Engager AFM28 At The EHA 2024 Congress
Affimed Announces Acceptance Of An Abstract On Preclinical Data Of Its Innate Cell Engager AFM28 At The EHA 2024 Congress
- Treatment with AFM28 innate cell engager (ICE), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML), led to dose-dependent tumor growth control in a validated in vivo mouse model
- AFM28 led to an effective reduction of CD123-expressing AML patient-derived leukemic blasts and stem cells in a newly engineered ex vivo bone marrow niche model
- 使用旨在靶向急性髓系白血病 (AML) 患者的 CD123 阳性癌细胞的 AFM28 先天细胞活化剂 (ICE) 进行治疗，在经过验证的体内小鼠模型中实现了剂量依赖性肿瘤生长控制
- 在新设计的体外骨髓利基模型中，AFM28 有效减少了表达 CD123 的急性髓细胞白血病患者衍生的白血病细胞和干细胞
MANNHEIM, Germany, May 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the publication of an abstract for the annual congress of the European Hematology Association (EHA), taking place in Madrid, Spain, June 13 – 16, 2024. The abstract presents preclinical data of Affimed's CD16A/CD123-targeting ICE, AFM28, in an acute myeloid leukemia (AML) mouse xenograft model and shows that increasing doses of AFM28 lead to a dose-dependent tumor growth control, resulting in an increased median life span of the treated mice compared to controls.
德国曼海姆，2024年5月14日（GLOBE NEWSWIRE）——致力于让患者恢复与生俱来的抗癌能力的临床阶段免疫肿瘤学公司Affimed N.V.（纳斯达克股票代码：AFMD）今天宣布发布将于2024年6月13日至16日在西班牙马德里举行的欧洲血液学协会（EHA）年会的摘要。该摘要提供了Affimed在急性髓系白血病（AML）小鼠异种移植模型中靶向CD16a/CD123的ICE AFM28 的临床前数据，并表明增加 AFM28 剂量会导致剂量依赖性肿瘤生长控制，与对照组相比，接受治疗的小鼠的中位寿命延长。
In addition, the abstract shows a data set from a collaboration with Dr. Hind Medyouf's group at the Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany. In a newly engineered ex vivo Human Organotypic Marrow Environment (HOME) model, the combination of AFM28 and allogeneic NK cells can lead to an effective reduction of CD123-expressing AML patient-derived leukemic blasts and stem cells. Importantly, the HOME model exhibits key immune suppressive cellular components, i.e. mesenchymal niche cells, enhancing the translational relevance of AFM28 preclinical activity.
此外，摘要显示了与德国美因河畔法兰克福Georg-Speyer-Haus肿瘤生物学和实验治疗研究所Hind Medyouf博士团队合作的数据集。在新设计的体外人类器官型骨髓环境 (HOME) 模型中，AFM28 和异体 NK 细胞的组合可以有效减少表达 CD123 的急性髓细胞白血病患者衍生的白血病细胞和干细胞。重要的是，HOME 模型表现出关键的免疫抑制细胞成分，即间充质利基细胞，增强了 AFM28 临床前活性的翻译相关性。
译文内容由第三方软件翻译。